Haemonetics (NYSE: HAE) reported Q2 EPS of $0.56, $0.02 better than the analyst estimate of $0.54. Revenue for the quarter came in at $242 million versus the consensus estimate of $233.45 million.

PDF LINK

For earnings history and earnings-related data on Haemonetics (HAE) click here.